Equity Research, Broker Reports, and media content on Poolbeg Pharma PLC

  • Access the latest forecasts, broker valuations, multiples, and video content from the city about Poolbeg Pharma PLC
  • See live updates from analysts, company announcements, and other news in a personalised/single dashboard

Poolbeg Pharma PLC

Company Profile

  • Profile:
  • Poolbeg Pharma plc is committed to the development and commercialisation of innovative medicines targeting diseases with a high unmet medical need. Its model focusses upon developing its exciting clinical assets and commercialising approved and marketed drugs to fund the development of its robust pipeline of innovative products, thereby driving significant value creation. Poolbeg is led by an experienced leadership team with a history of delivering significant shareholder value. The team has been strengthened by the appointment of three former members of the Amryt Pharma plc leadership team, with the intention of repeating Amryt's success and generating near term revenues. Poolbeg's clinical programmes target large addressable markets including cancer immunotherapy-induced CRS, infectious disease, and metabolic conditions such as obesity with the development of an oral GLP-1R agonist. It uses a cost-effective development philosophy to generate high quality human data to support partnering and further development. Its AI-led infectious disease programmes analyse unique data from human challenge trials to identify clinically relevant drug targets and treatments, leading to faster development and greater commercial appeal.

Research, Charts & Company Announcements

Research Tree provides access to ongoing research coverage, media content and regulatory news on Poolbeg Pharma PLC. We currently have 81 research reports from 5 professional analysts.

  • Open: 9.85p
  • Range Today: 9.65/10.0p
  • 52 Week: 6.38/12.1p
  • Daily Volume: 1.5m
  • Daily Liquidity: 0.31%
  • # Shares: 500.0m
  • Market Cap: 49.0m
  • Latest PE (hist):
  • Div Yield:
Date Source Announcement
20Mar24 07:00 RNS Poolbeg Pharma PLC - POLB 001 US Patent Update
22Feb24 07:00 RNS Poolbeg Pharma PLC - Director/PDMR Shareholding
19Feb24 13:42 RNS Poolbeg Pharma PLC - Director Share Purchase
15Feb24 07:00 RNS Poolbeg Pharma PLC - Board Role Change and Launch of EIP
12Feb24 07:00 RNS Poolbeg Pharma PLC - Market Opportunity for POLB 001 for CRS
17Jan24 07:00 RNS Poolbeg Pharma PLC - Further data shows POLB001 potential in cancer CRS
20Dec23 07:00 RNS Poolbeg Pharma PLC - RSV AI Drug Candidate Analysis Update
  • Frequency of research reports


  • Research reports on

    Poolbeg Pharma PLC

  • Providers covering

    Poolbeg Pharma PLC